BerganKDV Wealth Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

BerganKDV Wealth Management’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,500	Closed	-$1.15K	–	1104
2023 Q1	$1.15K	Hold	4,500	–	–	﹤0.01%	888
2022 Q4	$5.31K	Hold	4,500	–	–	﹤0.01%	667
2022 Q3	$9K	Hold	4,500	–	–	﹤0.01%	595
2022 Q2	$7K	Hold	4,500	–	–	﹤0.01%	654
2022 Q1	$23K	Hold	4,500	–	–	﹤0.01%	501
2021 Q4	$28K	Buy	4,500 +3,500	+350%	+$31.2K	﹤0.01%	499
2021 Q3	$10K	Buy	+1,000	New	+$9.89K	﹤0.01%	640

BerganKDV Wealth Management's PEAR Position: Q2 2023 in Review

BerganKDV Wealth Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 4,500 shares — an estimated $1.15K sold.

BerganKDV Wealth Management first reported a position in PEAR in Q3 2021 and held it in 7 quarters. The position peaked at $28K in Q4 2021. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

BerganKDV Wealth Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
BerganKDV Wealth Management sold 4,500 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $1.15K.
BerganKDV Wealth Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2021 and held it in 7 quarters.
BerganKDV Wealth Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $28K in Q4 2021.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on BerganKDV Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.